Tag - NTEC

Intec Pharma (NASDAQ:NTEC) reported that its Accordion Pill carbidopa/levodopa (AP-CD/LD) failed to meet its primary endpoint in a Phase 3 trial for Parkinson’s disease (PD). Intec’s extended release AP-CD/LD failed to...